Failure in any of these areas could have a material effect on our prospects.Unsuccessful clinical trials or procedures relating to products could have a material adverse effect on our prospects.Use of our products in unapproved circumstances could expose us to liabilities.We work with leading global physicians and research institutions who provide considerable knowledge and experience.Government and other third-party payors are increasingly attempting to contain health care costs by limiting both coverage and the level of reimbursement for medical products and services.HIPAA also imposes stringent data privacy and security requirements and the regulatory authority has imposed significant fines and penalties on organizations found to be out of compliance.The introduction of cost containment incentives, combined with closer scrutiny of health care expenditures by both private health insurers and employers, has resulted in increased discounts and contractual adjustments to hospital charges for services performed.Quality is extremely important due to the serious and costly consequences of a product failure.The availability of reimbursement affects which products customers purchase and the prices they are willing to pay.In addition, many of the devices we manufacture and sell are designed to be implanted in the human body for long periods of time.We may incur losses from product liability or other claims that could adversely affect our operating results.In June 2018, we issued $600.0 million of 4.3% fixed-rate unsecured senior notes (the "2018 Notes") due June 15, 2028.The Settlement Agreement resulted in us recording an estimated $367.9 million pretax charge in June 2020 related to past damages.Also discussed is our financial position as of December 31, 2022.As of December 31, 2022, our gross uncertain tax positions were $475.3 million.As of December 31, 2022, the carrying value of the 2018 Notes was $596.3 million.Interest ExpenseInterest expense was $19.2 million and $18.4 million in 2022 and 2021, respectively.Interest IncomeInterest income was $35.5 million and $17.4 million in 2022 and 2021, respectively.The tax reductions as compared to the local statutory rates were $247.4 million ($0.40 per diluted share) and $208.0 million ($0.33 per diluted share) for the years ended December 31, 2022 and 2021, respectively.Change in Fair Value of Contingent Consideration Liabilities, netThe change in fair value of contingent consideration liabilities resulted in income of $35.8 million and $124.1 million in in 2022 and 2021, respectively.The increase in interest expense resulted primarily from lower capitalized interest due to decreased facilities construction.Provision for Income Taxes ($in millions) Our effective income tax rate in 2022 and 2021 was 13.9% and 11.7%, respectively.We assert that $1.0 billion of our foreign earnings continue to be permanently reinvested and our intent is to repatriate $580.8 million of our foreign earnings as of December 31, 2022.